The Pros And Cons Of JE Vaccines
JE vaccination
The mouse brain derived killed-inactivated JE-VAX was the only commercially available vaccine all over the world for several decades though having adverse side effects, high production costs and the need for 2-3 doses plus boosters. In 2006 the production of this vaccine was halted due to significant allergic and neurological side effects. In 1988 in China a live-attenuated cell culture derived JE vaccine (SA14-14-2) was developed and has been administered to Chinese children since production was done. However, one vaccine named as IC51 has been licensed since 2009 in various countries including United States, Europe, Australia and India but in different names including IXIARO. But still, there are concerns with this and only
WHO recommend vaccine because of side effect. A vaccine of combination of live-attenuated vaccine based on a chimeric yellow fever/ JEV (ChimeriVax-JE) was developed recently and now is commercially available in Australia and Thailand. Though a number of vaccines have been developed for JEV, they are expensive and require a number of doses to maintain efficacy and immunity. The vaccination rates are often low in most of the JEV-endemic rural areas and also the vaccines are unlikely to result in eradication given human beings are the dead-end hosts as viremia is insufficient for onward transmission
The mouse brain derived killed-inactivated JE-VAX was the only commercially available vaccine all over the world for several decades though having adverse side effects, high production costs and the need for 2-3 doses plus boosters. In 2006 the production of this vaccine was halted due to significant allergic and neurological side effects. In 1988 in China a live-attenuated cell culture derived JE vaccine (SA14-14-2) was developed and has been administered to Chinese children since production was done. However, one vaccine named as IC51 has been licensed since 2009 in various countries including United States, Europe, Australia and India but in different names including IXIARO. But still, there are concerns with this and only
WHO recommend vaccine because of side effect. A vaccine of combination of live-attenuated vaccine based on a chimeric yellow fever/ JEV (ChimeriVax-JE) was developed recently and now is commercially available in Australia and Thailand. Though a number of vaccines have been developed for JEV, they are expensive and require a number of doses to maintain efficacy and immunity. The vaccination rates are often low in most of the JEV-endemic rural areas and also the vaccines are unlikely to result in eradication given human beings are the dead-end hosts as viremia is insufficient for onward transmission